Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Embraces Controversy Among Reasons To Convene Advisory Committees

This article was originally published in The Tan Sheet

Executive Summary

Applications for Rx-to-OTC switches will continue to be reviewed in advisory committee meetings because they often meet FDA's reasons to seek an advisory panel's recommendation under a proposed guidance

You may also be interested in...

Advisory Committee Vacancies Remain High As FDA Revs Up Search

With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies

FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials

FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance

Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process

FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than an overhaul of its practices


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts